<DOC>
	<DOCNO>NCT01109498</DOCNO>
	<brief_summary>LPLD rare autosomal recessive disorder , characterize presence mark chylomicronemia hence hypertriglyceridemia . Clinically severe manifestation chylomicronemia , acute pancreatitis , lethal . There effective therapy available modulate course illness prevent complication patient . The current clinical management consist severe reduction dietary fat hard almost impossible comply . LPLD subject continue experience pancreatitis attack , admit intensive care unit several occasion . Alipogene tiparvovec corrects restore lipoprotein lipase ( LPL ) function long term , hence revers symptom , halt disease progression prevents complication . Alipogene tiparvovec gene therapy ensure catabolically beneficial variant human LPL gene , LPL [ S447X ] express active relevant tissue human . Delivery gene realize via intramuscular injection adeno-associated viral vector , pseudotyped AAV1 capsid .</brief_summary>
	<brief_title>Safety Efficacy LPL-Deficient Subjects AMT-011 , Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase S447X</brief_title>
	<detailed_description>The CT-AMT-011-01 study open-label , dose-escalating study evaluate safety efficacy single intramuscular administration AMT-011 ( multiple site ) . The study perform Community Genomic medicineCenter ( CGMC ) Chicoutimi , Canada , supervision medical ethical committee accord local biosafety procedure . The study participant treat responsibility Principal Investigator specialise treatment lipid disorder . A total number 14 subject administer . Participants screen 3 week prior administration AMT-011 evaluate 12 week post administration study . After study , subject follow long term particular emphasis safety efficacy aspects LPL gene therapy use AMT-011 . Subjects evaluate clinical site 19 week , 26 week , 39 week , 1 year , 1.5 year , 2 year , 3 year , 4 year 5 year administration AMT-011 . The TG value obtain week 26 use secondary efficacy analysis .</detailed_description>
	<mesh_term>Hyperlipoproteinemia Type I</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Eligible Population Study participant must participate precede observation study ( Prep02 : Appendix III ) diagnose lipoprotein lipase deficiency , meet follow criterion : ( I ) Their lipoprotein lipase activity level postheparin plasma ≤20 % normal ; ( II ) Confirmed homozygocity compound heterozygocity mutation LPL gene ; ( III ) Postheparin plasma LPL mass &gt; 5 % normal ; ( IV ) Median fast plasma TG concentration &gt; 10.00mmol/L , determine basis 5 consecutive time point precede observation study history pancreatitis . General Health The participant must good general physical health , opinion investigator , clinically significant relevant abnormality medical history , abnormalities physical examination routine laboratory evaluation perform prior trial . Age Age ≥18 year old . Sex Male female . Females must nonchild bear potential negative pregnancy test breast feeding . Female subject must use appropriate contraception ( relevant ) spouse must use barrier contraception duration study ( 12 week ) . Males must practice barrier birth control spouse use appropriate contraception three consecutive semen sample , take least 75 day administration , negative AMT011 vector DNA . Compliance The participant willing fully comply study procedure requirement trial restriction lowfat diet ( see section 8.1 ) . Consent The participant mental ability give voluntary write informed consent participate study . Disease Apolipoprotein CII deficiency . Inflammatory muscle disease ( e.g . myositis , myopathy rhabdomolysis ) . Any current relevant previous history serious , severe unstable physical psychiatric illness , medical disorder may make participant unlikely fully complete study , condition present undue risk study medication procedure ( e.g . malignant neoplasia ) . Active infectious disease nature , include clinically active viral infection . Laboratory Parameters The follow blood screen test result exclusion participation : Platelet count &lt; 100 x 109 /L . Hemoglobin &lt; 7.0 mmol/L . Liver function disturbance ( bilirubin &gt; 2.50 x normal , transaminases &gt; 3 x ULN ) . CPK &gt; 3 x ULN . Creatinine &gt; 3 x ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>LPLD</keyword>
	<keyword>Lipoprotein Lipase Deficiency</keyword>
	<keyword>Chylomicronaemia</keyword>
	<keyword>Genetherapy</keyword>
	<keyword>AAV</keyword>
	<keyword>Alipogene Tiparvovec</keyword>
	<keyword>AMT-011</keyword>
	<keyword>Lipoprotein Lipase</keyword>
</DOC>